Celldex Therapeutics (CLDX) Stock
$29.87
+5.66% Close Nov 6
Open interactive chartCLDX stock price and performance
CLDX stock closed at $29.87 on Nov 6, 2026. The tables below use that final daily session.
- Last close
- $29.87
- Day range
- $27.82 to $30.15
- 52-week range
- $22.10 to $45.14
- From 52-week high
- −33.8%
- Average volume (50 days)
- 1.5M
- 1 week
- −0.8%
- 1 month
- +2.0%
- 3 months
- −30.5%
- Year to date
- +10.0%
- 1 year
- +25.9%
- 3 years
- +15.0%
- 5 years
- −35.0%
Is CLDX stock in an uptrend?
Not yet. CLDX stock is not in an uptrend by our rules: it does not meet the Minervini Trend Template criteria and neither Daily Pivot Breakout momentum filter is active. Price is below its 200-day moving average.
- Daily Pivot momentum filters
- 0 of 2 active
- 100-day ROC
- −7.6% filter at 40%: off
- 100-day EMA slope
- +10.7% filter at 25%: off
- Trend state
- Sideways
- Minervini Trend Template
- Not met on the latest scan
- 50-day average
- Below
- 150-day average
- Below
- 200-day average
- Below
- 200-day slope (1 month)
- +0.93%
- ATR (14) % of price
- 4.63%
Momentum filters from the Daily Pivot Breakout indicator: 100-day rate of change and 100-day EMA slope, each against its minimum.
Is CLDX stock in a Stage 2 uptrend?
No. CLDX stock is in Stage 3 (topping) by our Weinstein stage analysis: its 30-week moving average has flattened after an advance.
- Weinstein stage
- Stage 3 (topping)
- 30-week SMA
- $34.29
- 30-week slope (4 weeks)
- −0.75%
- Mansfield RS vs SPY
- -6.51
Weinstein stage analysis uses weekly closes against the 30-week moving average and Mansfield relative strength versus SPY. See the free Stage 2 stocks screener.
CLDX support and resistance levels
| Level | Price | From close |
|---|---|---|
| 150-day SMA | $34.40 | +15.2% |
| 30-week SMA | $34.29 | +14.8% |
| 50-day SMA | $32.93 | +10.2% |
| 200-day SMA | $32.74 | +9.6% |
| Daily Pivot resistance (pivot high) | $30.82 | +3.2% |
| 21-day EMA | $29.98 | +0.4% |
| 9-day EMA | $29.49 | −1.3% |
| Latest Daily Pivot low | $27.47 | −8.0% |
Levels above the close act as resistance, levels below as support. Last close $29.87.
CLDX breakout and scanner signals
| Scanner | Last signal (free view, 5 sessions late) | Past year |
|---|---|---|
| VCP | None in the last year | 0 |
| RSI Divergence | Oct 21, 2026 | 2 |
| Weinstein Stage Analysis | Sep 21, 2026 | 184 |
| Daily Pivot Breakout | None in the last year | 0 |
| Minervini Trend Template | Sep 14, 2026 | 116 |
| Episodic Pivot | None in the last year | 0 |
| Ichimoku TK cross | Sep 3, 2026 (bearish) | 9 |
| 9/21 EMA cross | Sep 1, 2026 (bearish) | 10 |
| Golden / Death Cross | None in the last year | 0 |
| RS Rating | None in the last year | 0 |
CLDX seasonality by month
- Jan+9.1%50% up
- Feb+1.8%48% up
- Mar−1.6%52% up
- Apr−0.8%52% up
- May−2.9%30% up
- Jun+20.3%59% up
- Jul−2.4%44% up
- Aug−2.5%44% up
- Sep−1.2%41% up
- Oct−0.9%52% up
- Nov+8.5%69% up
- Dec−1.9%46% up
Average monthly return over 26+ years of stored daily closes, and the share of years each month closed higher.
CLDX earnings history
| Reported | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Nov 5, 2026 | $-1.01 | $-0.96 | +5.0% |
| Aug 6, 2026 | $-1.06 | $-0.94 | +11.3% |
| May 7, 2026 | $-1.13 | $-1.18 | −4.4% |
| Feb 25, 2026 | $-1.00 | $-1.22 | −22.0% |
CLDX bull and bear case
What looks strong
- No strong points in the trend data on the latest scan.
What looks weak
- Neither Daily Pivot momentum filter is active (100-day ROC -7.6%, 100-day EMA slope 10.7%; the filters need 40% and 25%).
- Does not meet the Minervini Trend Template on the latest scan.
- Price is below the 200-day moving average.
- Short interest is 14.51% of shares outstanding.
- Net income over the last 12 months is negative.
Drawn only from the data on this page. Not a recommendation.
CLDX news and SEC filings, last 30 days
Source: SEC EDGAR.
CLDX insider trading and risks
Risk flags from the data
- Short interest is 14.51% of shares outstanding.
- Net income over the last 12 months is negative.
Insider trades: SEC Form 4 open-market purchases and sales.
CLDX valuation and fundamentals
- Market cap
- $2.35B
- Enterprise value
- $1.71B
- P/E (trailing)
- -7.7
- P/E (forward)
- -7.1
- PEG
- -0.72
- Price to sales
- 14,848.99
- Price to book
- 3.61
- EV to EBITDA
- -5.2
- Gross margin
- –
- Operating margin
- −211,684.8%
- Profit margin
- 0.0%
- Return on equity
- −49.5%
- Revenue (TTM)
- $158,000
- Revenue growth (quarter, y/y)
- +46.7%
- Cash
- $650.3M
- Debt
- $9.9M
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $1.5M | −$258.8M | −$210.9M |
| 2024 | $7.0M | −$157.9M | −$135.7M |
| 2023 | $6.9M | −$141.4M | −$118.2M |
| 2022 | $2.4M | −$112.3M | −$100.0M |
CLDX dividends and splits
- Dividend yield
- 0.00%
- Payout ratio
- 0.0%
Stock splits: 1-for-15 split on Feb 11, 2019, 1-for-12 split on Mar 10, 2008.
Who owns CLDX?
- Shares outstanding
- 78.5M
- Float
- 73.0M
- Held by insiders
- +0.3%
- Held by institutions
- +110.0%
- Short interest (% of shares)
- +14.5%
- Days to cover
- 4.3
What does Celldex Therapeutics Inc. do?
- CEO
- Mr. Anthony S. Marucci M.B.A.
- Employees
- 198
- Headquarters
- Hampton, NJ, United States
- Website
- celldex.com
